Related Experiment Video
Updated: Jun 2, 2025
Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
Published on: October 10, 2012
Adeno-Associated Viruses as Gene Delivery Tools for Diabetic Heart Disease and Failure: Key Considerations for
Kate L Weeks1, Bianca C Bernardo2
1Department of Anatomy & Physiology, University of Melbourne, Vic, Australia; Baker Department of Cardiometabolic Health, University of Melbourne, Vic, Australia; Central Clinical School, Monash University, Melbourne, Vic, Australia.
Insights
Diabetes significantly increases heart disease risk, leading to diabetic cardiomyopathy. Gene therapy, using tools like adeno-associated viral vectors, shows promise for treating this condition by targeting specific molecular pathways.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
- Gene Therapy
Background:
- Diabetes mellitus is a global epidemic with a high prevalence of cardiovascular complications.
- Diabetic cardiomyopathy is a specific heart condition in diabetic patients, contributing significantly to mortality.
- Current treatments for diabetic cardiomyopathy are limited, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the current progress in gene therapy for diabetic cardiomyopathy.
- To identify challenges and experimental considerations in developing gene therapy for the diabetic heart.
- To discuss the potential of gene therapy as an innovative treatment for diabetic heart conditions.
Main Methods:
- Review of existing research on gene therapy for diabetic cardiomyopathy.
- Analysis of molecular pathways affected in diabetic heart disease.
- Discussion of gene therapy vectors, such as adeno-associated viral vectors.
- Exploration of experimental designs and challenges in preclinical and clinical studies.
Main Results:
- Gene therapy approaches are being developed to target specific molecular defects in diabetic cardiomyopathy.
- Adeno-associated viral vectors are a promising tool for delivering therapeutic genes.
- Significant challenges remain in optimizing delivery, efficacy, and safety of gene therapy for the diabetic heart.
Conclusions:
- Gene therapy represents a promising frontier for treating diabetic cardiomyopathy.
- Further research and careful experimental design are crucial for overcoming challenges in gene therapy development.
- Targeting molecular pathways offers a potential strategy to improve cardiovascular outcomes in diabetic patients.
Abstract:
Diabetes is becoming more common worldwide, and people with diabetes are twice as likely to experience heart problems compared to those without diabetes. These cardiovascular complications are the foremost cause of mortality among people with diabetes. A specific form of heart failure known as "diabetic cardiomyopathy" can develop in individuals with diabetes. There are no treatments specifically approved for diabetic cardiomyopathy. Ongoing research is exploring innovative treatments, including the development of gene therapy techniques (e.g., adeno-associated viral vectors) designed to target specific molecular pathways affected in the disease. Here, we discuss the progress, challenges, and experimental considerations of gene therapy for the diabetic heart.
More Related Videos
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
11:11Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts
Published on: December 17, 2016